Clarithromycin 500 mg film-coated tablets

Quốc gia: Ai-len

Ngôn ngữ: Tiếng Anh

Nguồn: HPRA (Health Products Regulatory Authority)

Thành phần hoạt chất:

Clarithromycin

Sẵn có từ:

Sun Pharmaceutical Industries Europe B.V.

Mã ATC:

J01FA; J01FA09

INN (Tên quốc tế):

Clarithromycin

Liều dùng:

500 milligram(s)

Dạng dược phẩm:

Film-coated tablet

Loại thuốc theo toa:

Product subject to prescription which may not be renewed (A)

Khu trị liệu:

Macrolides; clarithromycin

Tình trạng ủy quyền:

Marketed

Ngày ủy quyền:

2006-10-20

Tờ rơi thông tin

V047
PACKAGE LEAFLET: INFORMATION FOR THE USER
CLARITHROMYCIN 500 MG FILM-COATED TABLETS
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
_ _
WHAT IS IN THIS LEAFLET
1.
What Clarithromycin Film-Coated Tablets are and what they are used for
2.
What you need to know before you take Clarithromycin Film-Coated
Tablets
3.
How to take Clarithromycin Film-Coated Tablets
4.
Possible side effects
5.
How to store Clarithromycin Film-Coated Tablets
6.
Contents of the pack and other information
_ _
1.
WHAT CLARITHROMYCIN FILM-COATED TABLETS ARE AND WHAT THEY ARE USED FOR
Clarithromycin Film-Coated Tablets
contains the active ingredient clarithromycin,
which is an macrolide antibiotic which stop the growth of bacteria
which cause
infections.
Clarithromycin Film-Coated Tablets is indicated for use in adults and
adolescents over
12 years of age for the treatment of infections caused by
micro-organisms sensitive to
clarithromycin. These infections include:
•
Upper respiratory tract infections (e.g. pharyngitis, sinusitis)
•
Lower respiratory tract infections (e.g. bronchitis, pneumonia)
•
Acute otitis media
•
Skin and soft tissue infections (e.g. impetigo, folliculitis,
cellulitis, abscesses)
•
Disseminated or localised mycobacterial infections
In HIV-infected patients (CD4 cell count ≤100/mm3), Clarithromycin
is indicated for the prevention
of disseminated infections caused by the Mycobacterium avium (MAC)
complex.
In patients with duodenal ulceration and diagnostically confirmed
Helicobacter pylori infection,
clarithromycin treatm

Đặc tính sản phẩm

Health Products Regulatory Authority
28 October 2022
CRN00CVZ4
Page 1 of 17
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Clarithromycin 500 mg film-coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains clarithromycin 500 mg.
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Film-coated Tablet
Light yellow coloured, oval shaped biconvex film coated tablets, with
“C” and “2” embossed on either side of a breakline on
one side and notched on both sides. The tablet can be divided into
equal doses.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Consideration should be given to official guidance on the appropriate
use of antibacterial agents.
Clarithromycin is indicated for use in adults and adolescents older
than 12 years for the treatment of infections caused by
micro-organisms sensitive to clarithromycin. These infections include:

Lower respiratory tract infections for example bronchitis, and
pneumonia (see section 4.4 and 5.1 regarding
Sensitivity Testing).

Upper respiratory tract infections for example sinusitis and
pharyngitis.

Acute otitis media

Skin and soft tissue infections (e.g. impetigo, folliculitis,
cellulitis, abscesses) (see section 4.4 and 5.1 regarding
Sensitivity Testing)

Disseminated or localised _Mycobacterium avium _or _Mycobacterium
intracellulare_ infections; localised
_Mycobacterium chelonae_, _Mycobacterium fortuitum _or _Mycobacterium
kansasii_ infections.
In HIV-infected patients (CD4 cell count ≤100 / mm
3
), clarithromycin is indicated for the prevention of disseminated
infections
caused by the _Mycobacterium avium_ (MAC) complex.
In patients with duodenal ulceration and diagnostically confirmed
_Helicobacter pylori _infection, clarithromycin treatment is
recommended simultaneously with preparations that suppress gastric
acid secretion and other antibiotics.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Dosage
Patients with respiratory tract, skin and soft tissue and acute otitis
media infectio